iPSC-derived CAR NK / Fate Therapeutics, Ono Pharmaceutical - LARVOL DELTA

Phase 1 Translational Assessment of an Off-The-Shelf CAR NK Cell Armed with Alloimmune Defense Technology for Conditioning-free Therapy (ASGCT 2025) - P1 | "Intense conditioning chemotherapy (CCT), often consisting of cyclophosphamide and fludarabine, is commonly administered to patients prior to treatment with CAR therapies, although CCT is associated with severe toxicities. We developed FT522, a next generation iPSC-derived CAR NK cell therapy, that is designed to confer therapeutic benefit without requiring the administration of CCT...Collectively, our preclinical and early-stage translational data from our Phase 1 study of FT522 demonstrate that ADR is capable of enabling anti-tumor activity, promoting functional persistence, and avoiding immune rejection without requiring administration of CCT to patients. Disease Focus of Abstract:Lymphoma"

P1 data • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD4 • IL15

Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection (ASH 2022) - "Similar to primary CAR T cells, multiplexed edited CD54-/-CD58-/-B2M-/-CIITA-/- iNK cells showed normal growth kinetics and were resistant to rejection by activated allogeneic NK cells in MLR assays. Together, these data demonstrate that reverse-engineering of common tumor escape mechanisms, which render target cells less susceptible to immune synapse formation, is an effective strategy to avert immune rejection of allogeneic CAR T and iPSC-derived CAR NK cells."

IO biomarker • Immune Modulation • Inflammation • Oncology • B2M • CD58 • CD8 • HLA-C • HLA-E • ICAM1 • KIR2DS2 • KLRC1